Bavencio

Approved Uses

Bavencio is a prescription medicine used to treat several specific types of cancer that are advanced or have spread to other parts of the body. It belongs to a class of drugs known as immunotherapy, which helps the immune system attack cancer cells.

• Merkel Cell Carcinoma: Bavencio is used to treat adults and children 12 years of age and older with this rare type of skin cancer when it has spread (metastatic).
• Urothelial Carcinoma: This medication is used for advanced bladder or urinary tract cancer. It may be prescribed as a maintenance treatment if the cancer has not worsened after initial platinum-based chemotherapy. It is also used for patients whose cancer has spread or progressed during or after chemotherapy.
• Renal Cell Carcinoma: Bavencio is used as a first-line treatment for advanced kidney cancer. For this condition, it is used in combination with another medication called axitinib.

Mechanism of Action

Bavencio belongs to a class of drugs known as PD-L1 blocking antibodies. It is a type of immunotherapy called a monoclonal antibody, which is designed to target specific proteins in the body to help fight disease.

Unmasking Cancer Cells

The immune system uses certain "checkpoint" proteins to prevent it from attacking healthy cells. Some cancer cells take advantage of this system by producing a protein called programmed death-ligand 1 (PD-L1). When PD-L1 binds to receptors on T-cells (a type of white blood cell), it sends a signal that tells the immune system not to attack. This allows the cancer to hide and grow undetected.

Bavencio works by attaching itself to the PD-L1 protein on the surface of cancer cells. By blocking this protein, the drug prevents it from sending the "stop" signal to the immune system. This unmasks the cancer cells, allowing T-cells to recognize them as a threat and launch an attack against the tumor.

Immune Cell Recruitment

In addition to blocking the PD-L1 signal, Bavencio may also help the immune system through a process called antibody-dependent cell-mediated cytotoxicity. In this process, the drug acts as a marker that helps recruit other immune cells, such as natural killer cells, to directly target and destroy the cancer cells to which the drug has attached.

Common Side Effects

Many people receiving Bavencio experience mild to moderate side effects. These may include:

• Feeling tired or weak (fatigue)
• Muscle, bone, or joint pain
• Nausea and diarrhea
• Decreased appetite and weight loss
• Rash or itchy skin
• Swelling in the hands, feet, or ankles
• Cough or shortness of breath
• Constipation
• Headache or dizziness

Serious Side Effects

Bavencio works by stimulating the immune system, which can sometimes cause the immune system to attack healthy tissues and organs. These reactions can be severe or life-threatening and may affect any part of the body. Seek medical help immediately for symptoms such as:

• Lung problems: New or worsening cough, chest pain, or shortness of breath.
• Intestinal problems: Severe stomach pain, diarrhea, or stool that is black, tarry, or bloody.
• Liver problems: Yellowing of the skin or eyes (jaundice), dark urine, or severe nausea and vomiting.
• Hormone gland problems: Rapid heartbeat, extreme tiredness, weight changes, or mood changes.
• Kidney problems: Changes in the amount or color of urine, or swelling in the ankles.
• Skin problems: Severe rash, blistering, or peeling.

Infusion-related reactions can also occur during or shortly after the medication is administered. Symptoms may include chills, shaking, fever, flushing, or low blood pressure. Healthcare providers typically monitor patients closely during the infusion to manage these reactions.

Immune System Reactions

Bavencio works by helping the immune system attack cancer cells. However, it may also cause the immune system to attack healthy organs and tissues. These immune-mediated reactions can occur in any part of the body and may become serious or life-threatening. Common areas affected include:

• Lungs: Inflammation of the lungs (pneumonitis) can cause new or worsening cough, chest pain, or shortness of breath.
• Intestines: Inflammation of the colon (colitis) may lead to diarrhea, severe stomach pain, or blood in the stool.
• Liver: Hepatitis can cause yellowing of the skin or eyes (jaundice), severe nausea, or dark urine.
• Hormone Glands: Problems can occur in the thyroid, pituitary, or adrenal glands, as well as the development of type 1 diabetes.
• Kidneys: Kidney inflammation (nephritis) may result in changes in urine color or amount.
• Skin: Severe rashes, itching, or blistering may occur.

Infusion-Related Reactions

Serious reactions can happen during or shortly after the intravenous infusion. Symptoms may include chills, shaking, fever, flushing, shortness of breath, or dizziness. Medical staff typically monitor for these signs during treatment.

Pregnancy and Breastfeeding

This medication can cause harm to an unborn baby. Effective birth control is generally recommended during treatment and for at least one month after the final dose. Breastfeeding is typically discouraged during treatment and for a period following the last dose.

Monitoring

Regular blood tests are often necessary to monitor liver function, kidney health, and hormone levels to detect potential immune-mediated reactions early.

Pregnancy

Bavencio can cause harm to a fetus when administered to a pregnant person. Before starting treatment, healthcare providers typically require a pregnancy test for individuals who are able to become pregnant to ensure they are not pregnant. It is important to use effective birth control during treatment and for at least one month after the final dose. If you become pregnant or think you might be pregnant while receiving this medication, you should contact your healthcare provider immediately to discuss the potential risks.

Breastfeeding

It is not known whether Bavencio passes into breast milk. Because of the potential for serious side effects in a nursing infant, it is recommended that breastfeeding be avoided during treatment and for at least one month after the last dose. Individuals should discuss their breastfeeding plans with a healthcare provider to determine the safest course of action.

Available Forms

Bavencio is supplied as a sterile, preservative-free liquid solution in a vial. The solution is clear and colorless to slightly yellow.

Route of Administration

This medication is administered only as an intravenous infusion. It is given slowly into a vein by a doctor or nurse in a medical facility, such as a hospital or infusion center. The solution is typically diluted with a compatible saline solution before it is administered to the patient.

FDA Approval History

Bavencio, the brand name for the drug avelumab, received its initial FDA approval in 2017. It is a type of immunotherapy known as a PD-L1 blocking antibody, which works by helping the immune system identify and attack cancer cells.

Approved Indications

The FDA has approved Bavencio for several specific medical uses:

• Merkel Cell Carcinoma: For the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (a rare form of skin cancer).
• Urothelial Carcinoma: For patients with locally advanced or metastatic bladder or urinary tract cancer that has progressed during or after platinum-containing chemotherapy. It is also approved as a maintenance treatment for patients whose cancer has not progressed following first-line platinum-based chemotherapy.
• Renal Cell Carcinoma: In combination with the medication axitinib for the first-line treatment of patients with advanced kidney cancer.

Regulatory Monitoring and Safety

The FDA monitors the safety of Bavencio through the FDA Adverse Event Reporting System (FAERS). Regulatory reviews have identified potential signals of serious risks, specifically immune-mediated adverse reactions. These reactions occur when the drug causes the immune system to attack healthy organs or tissues, such as the lungs, liver, colon, or endocrine glands.

Some of Bavencio's indications were granted under the FDA's accelerated approval program. This program allows for earlier approval of drugs that treat serious conditions and fill an unmet medical need based on a surrogate endpoint, such as tumor shrinkage. Continued approval for these specific uses may be contingent upon the results of further clinical trials that confirm the drug's clinical benefit.

Factors Affecting Cost

The total price of Bavencio treatment is influenced by various elements. Because this medication is a biologic drug administered as an intravenous infusion by a healthcare professional, costs are not limited to the drug itself.

• Insurance Coverage: Your out-of-pocket expenses will vary based on whether you have private insurance, Medicare, or Medicaid. Each plan has different rules regarding deductibles, co-pays, and coinsurance for specialty medications.
• Administration Fees: Since Bavencio must be given in a clinical setting, you may be billed for the healthcare provider's time, infusion equipment, and facility fees.
• Treatment Schedule: The frequency of your infusions and the duration of your treatment course will impact the cumulative cost.

Financial Assistance

Patients may have access to programs designed to reduce the financial burden of treatment. These options often include:

• Co-pay Assistance: Programs may be available for patients with commercial insurance to help cover out-of-pocket costs.
• Patient Assistance Programs: The manufacturer may provide the medication at a lower cost or for free to individuals who meet specific financial and insurance eligibility criteria.

To understand your specific costs, it is best to contact your insurance provider for a summary of benefits and speak with the financial counselor at your treatment center.